Compare HSBC Holdings plc (HSBC) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Natera Inc. Common Stock — how do they compare? HSBC Holdings plc trades at $94.89 (market cap $323.18B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: HSBC Holdings plc is far larger — about 5.7× Natera Inc. Common Stock's market cap, and HSBC Holdings plc pays a 3.95% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 37 Days and Natera Inc. Common Stock for 0 Days on average.
| HSBC | NTRA | |
|---|---|---|
Market Cap | $323.18B | $57.03B |
Volume | 1,876,560 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $107.86 | $425.64 |
52-Week Low | $65.67 | $179.42 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $229.73B | $56.18B |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $94.85, up 0.56% today, with a bearish technical signal from moving averages and ADX. The stock shows solid fundamentals with a P/E of 13.55, net income margin of 34.54%, and recent earnings beats in Q4 2025 and Q2 2026. Recent news highlights strategic expansions in TMT banking and India equity broking, alongside a planned CFO transition in 2027.
The outlook is mixed: valuation appears reasonable and profitability is strong, but technical indicators signal caution and analyst consensus leans Hold. Key risks include execution of growth initiatives and macroeconomic pressures. The stock offers income with a $0.50 dividend, but investors should weigh near-term technical weakness against long-term fundamental strength.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
